Type of investment:
Management Buy-Out (MBO)
Established in 1998 through the spin-off of Novartis’ plant in Milan, Mipharm is an Italian leading Pharmaceutical Contract Development & Manufacturing Organization (“CDMO”). The company is engaged in the manufacturing and packaging of a wide range of pharmaceuticals, with a customer base consisting of Big Pharma and generic pharmaceutical manufacturers globally. In addition, through its internal R&D department, Mipharm provides R&D services for new products and clinical trials. During MCP’s holding period, the company undertook a process to manage the top line and rationalize operating costs.